External Validation of UDCA Response Score in Slovak and Croatian Patients with Primary Biliary Cholangitis.
Can J Gastroenterol Hepatol
; 2021: 9928065, 2021.
Article
en En
| MEDLINE
| ID: mdl-34258254
ABSTRACT
Background:
Ursodeoxycholic acid response score (URS) is a prognostic model that estimates the baseline probability of treatment response after 12 months of ursodeoxycholic acid (UDCA) therapy in patients with primary biliary cholangitis (PBC).Aim:
To independently evaluate the predictive performance of the URS model.Methods:
We used a cohort of Slovak and Croatian treatment-naïve PBC patients to quantify the discrimination ability using the area under receiver operating characteristic curve (AUROC) and its 95% confidence interval (CI). Furthermore, we evaluated the calibration using calibration belts. The primary outcome was treatment response after 12 months of UDCA therapy defined as values of alkaline phosphatase ≤1.67 × upper limit of normal.Results:
One hundred and ninety-four patients were included. Median pretreatment age was 56 years (interquartile range 49-62). Treatment response was achieved in 79.38% of patients. AUROC of the URS was 0.81 (95% CI 0.73-0.88) and the calibration belt revealed that response rates were correctly estimated by predicted probabilities.Conclusion:
Our results confirm that the URS can be used in treatment-naïve PBC patients for estimating the treatment response probability after 12 months of UDCA therapy.
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Ácido Ursodesoxicólico
/
Cirrosis Hepática Biliar
Tipo de estudio:
Etiology_studies
/
Incidence_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Humans
/
Middle aged
País como asunto:
Europa
Idioma:
En
Año:
2021
Tipo del documento:
Article